Fulcrum Therapeutics : Corporate Overview Presentation- January 2023

FULC

January 2023

Disclaimer and Notice

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including express of implied statements regarding the development status of Fulcrum's product candidates, the potential advantages and therapeutic potential of Fulcrum's product candidates planned meetings with regulatory agencies and availability of clinical trial data. All statements, other than statements of historical facts, contained in this press release, including statements regarding Fulcrum's strategy, future operations, future financial position, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate,"

"expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended

to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward- looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward- looking statements. These risks and uncertainties include, but are not limited to, risks associated with Fulcrum's ability to obtain and maintain necessary approvals from the FDA and other regulatory authorities; continue to advance its product candidates in clinical trials; initiate and enroll clinical trials on the timeline expected or at all; correctly estimate the potential patient population and/or market for Fulcrum's product candidates; replicate in clinical trials positive results found in preclinical studies and/or earlier-stage clinical trials of losmapimod, FTX-6058, and any other product candidates; obtain, maintain or protect intellectual property rights related to its product candidates; manage expenses; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Fulcrum's actual results to differ from those contained in the forward-looking statements, see the "Risk Factors" section, as well as discussions of potential risks, uncertainties and other important factors, in Fulcrum's most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Fulcrum's views as of the date hereof and should not be relied upon as representing Fulcrum's views as of any date subsequent to the date hereof. The Fulcrum anticipates that subsequent events and developments will cause Fulcrum's views to change. However, while the Fulcrum may elect to update these forward-looking statements at some point in the future, the Fulcrum specifically disclaims any obligation to do so.

FULCRUM THERAPEUTICS

2

Unlocking the Power

of Small Molecules to Change the Course of Genetically Defined Rare Diseases

Founded in 2015

IPO in 2019

Ticker: FULC

01 Diversified biotech developing oral small molecules capable of modifying gene expression: two wholly owned programs in clinical development

02

Losmapimod: first-to-market potential in facioscapulohumeral muscular dystrophy (FSHD); granted Fast Track Designation

03

FTX-6058: potential best-in-class oral small molecule HbF inducer for sickle cell disease (SCD); granted Fast Track Designation

04

Discovery engine validated by two clinical programs Cash runway to late 2024 through near-term value drivers

3

Pipeline and Catalysts

Indication	MOA	Preclinical	Phase 1	Phase 2	Phase 3	2023 Catalysts

Wholly Owned Clinical Programs

FSHD	Losmapimod
(DUX4 Inhibitor)
SCD	FTX-6058
(Oral HbF Inducer)

Wholly Owned Discovery Programs

Blood Disorder

Neurologic Disorder

Muscle Disorder

Collaborations

Cardiomyopathies

Complete Phase 3 enrollment in 2H'23

Phase 1b data update in 4Q'23

FULCRUM THERAPEUTICS

HbF: Fetal hemoglobin

4

Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)